Our in vitro study also indicated that AREG significantly enhanced the growth of cetuximab-sensitive RAS/BRAF wild-type colorectal cancer cell lines with increased phosphorylation of AKT and ERK1/2. This evidence concerns the gene MAPK3 and colorectal cancer.